Marksans Pharma
MARKSANSNSE

Marksans Pharma

₹187.763.66 (1.99%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events

Performance

Today’s low
185.00
Today’s high
191.10
52 week low
155.00
52 week high
270.70
Open price
185.70
Previous close
184.10
Live volume
8,37,935
Lower circuit
150.21
Upper circuit
225.31

Fundamentals

Market Cap
₹8,363Cr
ROE
13.08%
P/E Ratio(TTM)
23.13
EPS(TTM)
7.98
P/B Ratio
3.11
Dividend Yield
0.43%
Industry P/E
33.33
Book Value
59.32
Debt to Equity
0.12
Face Value
1

Financial performance

Quarterly
Yearly
All Financials
DEC '25
Revenue (Cr)
₹775
+4.39%
Profit (Cr)
₹114
+14.68%
0200400600800
Dec '24
Mar '25
Jun '25
Sep '25
Dec '25
Revenue growthValue
1Y (TTM)+9%
3Y CAGR+21%
Profit growthValue
1Y (TTM)+8%
3Y CAGR+27%

About

Marksans Pharma is a trusted global pharmaceutical company that develops, manufactures, and distributes both over-the-counter (OTC) and prescription (Rx) drugs for regulated markets. Its guiding vision is to transform into a respected, profitable, and integrated global pharmaceutical enterprise by delivering quality formulations to people. The company's overall manufacturing capacity has impressively reached 26 billion units per year, a fourfold increase achieved over several years.;
CEO/MD
NA
Founded in
--
NSE symbol
MARKSANS

Shareholding Pattern

Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Promoters
43.87%
Retail And Others
32.79%
Foreign Institutions
16.76%
Mutual Funds
4.66%
Other Domestic Institutions
1.91%

Mutual Funds Invested (4)

Similar stocks

StockMkt price (1D)52 week performanceMarket capP/E ratioP/B ratio
Natco PharmaNATCOPHARM
₹1,093.60
-0.50 (0.05%)
L
    H
    19,596.4112.62.27
    ₹1,316.20
    -11.40 (0.86%)
    L
      H
      18,343.7738.975.22
      ₹704.55
      -0.60 (0.09%)
      L
        H
        17,470.9232.034.08
        ₹926.85
        -15.60 (1.66%)
        L
          H
          14,989.3334.92.27
          Livesquawk
          Marksans Pharma gets USFDA nod for benzonatate capsules USP 100 mg and 200 mg. This approval allows Marksans Pharma to market the product in the US.
          Livesquawk
          Marksans Pharma's 9MFY26 EBITDA margin is 19.4%, aligning with its 19-20% full-year guidance.
          Livesquawk
          Marksans Pharma's Q3 net profit rose to ₹1.13B from ₹1.05B YoY.
          2026
          5
          Feb
          Quarterly Result
          Release date
          2025
          13
          Nov
          Quarterly Result
          Release date
          12
          Aug
          Quarterly Result
          Release date

          1
          Aug
          Dividend
          Ex date
          ₹0.80
          per share

          For each share you hold, you will receive ₹0.80
          Dividend amount₹0.80 per share
          Dividend TypeFinal
          Ex Date1 Aug ‘25
          Record Date1 Aug ‘25
          Announcement date19 May ‘25

          19
          May
          Dividend
          Announced
          ₹0.80
          per share

          For each share you hold, you will receive ₹0.80
          Dividend amount₹0.80 per share
          Dividend TypeFinal
          Ex Date1 Aug ‘25
          Record Date1 Aug ‘25
          Announcement date19 May ‘25
          2024

          17
          Sep
          Dividend
          Ex date
          ₹0.60
          per share

          For each share you hold, you will receive ₹0.60
          Dividend amount₹0.60 per share
          Dividend TypeFinal
          Ex Date17 Sep ‘24
          Record Date17 Sep ‘24
          Announcement date30 May ‘24

          30
          May
          Dividend
          Announced
          ₹0.60
          per share

          For each share you hold, you will receive ₹0.60
          Dividend amount₹0.60 per share
          Dividend TypeFinal
          Ex Date17 Sep ‘24
          Record Date17 Sep ‘24
          Announcement date30 May ‘24
          Events calendar
          View upcoming events in other stocks